Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan;138(1):e70176.
doi: 10.1111/bcpt.70176.

Perspectives on the Influence of Pharmaceutical and MedTech Companies on Deprescribing Decisions and Conference Sponsorship: A Survey Study

Katharina Tabea Jungo  1   2 , Cynthia M Boyd  3 , Barbara Farrell  4   5 , Caroline McCarthy  6
Affiliations

Perspectives on the Influence of Pharmaceutical and MedTech Companies on Deprescribing Decisions and Conference Sponsorship: A Survey Study

Katharina Tabea Jungo et al. Basic Clin Pharmacol Toxicol. 2026 Jan.

Abstract

Background: The involvement and sponsorship of pharmaceutical and medical technology (MedTech) companies in deprescribing and medication optimization activities raise questions about conflicts of interest. We surveyed registrants and attendees of previous International Conferences on Deprescribing to explore views on the acceptability and impact of such involvement and sponsorship.

Methods: We conducted two unlinked, anonymous cross-sectional surveys among all participants of the 2022 and 2024 International Conferences on Deprescribing (376 unique email addresses). The first survey addressed pharmaceutical companies; the second focused on MedTech. Quantitative data were analysed descriptively. Free-text responses were analysed thematically.

Findings: The response rate was 33% (n = 116/355) for the pharmaceutical survey and 20% (n = 68/335) for the MedTech survey. Trust in deprescribing information was low for pharmaceutical companies, with 52% reporting distrust (n = 47/91). Trust was somewhat higher for MedTech companies, with 27% expressing distrust (n = 14/52). Forty-eight percent (n = 42/87) said they would be less likely to attend an international deprescribing conference with pharmaceutical sponsorship versus 26% (n = 13/49) for MedTech. Among clinicians and clinician-scientists who completed the survey, 27% (n = 18/67) said pharmaceutical companies, and 27% (n = 10/37) said MedTech companies, somewhat or very much influence their deprescribing decisions.

Conclusions: Despite broad scepticism about private-sector involvement and sponsorship of deprescribing activities, views varied.

Plain language summary

We surveyed clinicians and researchers who attended or registered for two international conferences about safely reducing or stopping medications (deprescribing). We collected their views on drug and medical technology company (MedTech) involvement and sponsorship of future related events. We sent two short surveys that were not linked. The first survey explored views about drug company sponsorship and had a response rate of 33%. The second survey explored views about MedTech sponsorship and had a response rate of 27%. Most people were sceptical about sponsorship from either source but trusted MedTech companies a bit more than drug companies.

PubMed Disclaimer

References

    1. B. Farrell, K. Pottie, C. H. Rojas‐Fernandez, L. M. Bjerre, W. Thompson, and V. Welch, “Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing,” PLoS ONE 11, no. 8 (2016): e0161248.
    1. G. Nyborg, J. Straand, and M. Brekke, “Inappropriate Prescribing for the Elderly—A Modern Epidemic?,” European Journal of Clinical Pharmacology 68, no. 7 (2012): 1085–1094.
    1. R. Daunt, D. Curtin, and D. O'Mahony, “Polypharmacy Stewardship: A Novel Approach to Tackle a Major Public Health Crisis,” Lancet Healthy Longevity 4, no. 5 (2023): e228–e235.
    1. A. M. Linsky, A. Motala, M. Booth, E. Lawson, and P. G. Shekelle, “Deprescribing in Community‐Dwelling Older Adults: A Systematic Review and Meta‐Analysis,” JAMA Network Open 8, no. 5 (2025): e259375.
    1. D. Zhou, Z. Chen, and F. Tian, “Deprescribing Interventions for Older Patients: A Systematic Review and Meta‐Analysis,” Journal of the American Medical Directors Association 24, no. 11 (2023): 1718–1725.

LinkOut - more resources